Syros Pharmaceuticals 관리

관리 기준 확인 2/4

Syros Pharmaceuticals CEO는 Conley Chee, Dec2023 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $ 1.04M, 46% 로 구성됩니다. 46% 급여 및 54% 보너스(회사 주식 및 옵션 포함). 는 € 36.86K 가치에 해당하는 회사 주식의 0.49% 직접 소유합니다. 36.86K. 경영진과 이사회의 평균 재임 기간은 각각 2.6 년과 11.6 년입니다.

주요 정보

Conley Chee

최고 경영자

US$1.0m

총 보상

CEO 급여 비율	46.0%
CEO 임기	less than a year
CEO 소유권	0.5%
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	11.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Conley Chee 의 보수는 Syros Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$132m
Mar 31 2024	n/a	n/a	-US$144m
Dec 31 2023	US$1m	US$479k	-US$165m

보상 대 시장: Conley 의 총 보상 ($USD 1.04M )은 German 시장( $USD 471.14K ).

보상과 수익: Conley 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Conley Chee (54 yo)

less than a year

테뉴어

US$1,041,697

보상

Mr. Conley Chee serves as President, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc. since December 02, 2023. He served as Chief Commercial Officer at Syros Pharmaceuticals, Inc. since Se...

리더십 팀

이름	위치	테뉴어	보상	소유권
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.49% € 36.9k
Richard Young	Scientific Founder & Member of Scientific Advisory Board	no data	US$82.15k	0.040% € 3.0k
Jason Haas	Chief Financial Officer	3.1yrs	US$833.02k	0% € 0
David Roth	Chief Medical Officer	8.9yrs	US$876.53k	0% € 0
James Bradner	Founder	no data	데이터 없음	데이터 없음
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gerald Quirk	Chief Legal & Compliance Officer and Chief Business Officer	2.1yrs	US$1.46m	0% € 0
Lisa Roberts	Vice President of Human Resources	1.8yrs	데이터 없음	데이터 없음
Kristin Stephens	Chief Development Officer	4.4yrs	데이터 없음	0% € 0

2.6yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 0S90 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.49% € 36.9k
Richard Young	Scientific Founder & Member of Scientific Advisory Board	11.6yrs	US$82.15k	0.040% € 3.0k
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	11.6yrs	데이터 없음	데이터 없음
Peter Karl Wirth	Independent Chairman	7.8yrs	US$110.40k	0.060% € 4.5k
Mark Murcko	Member of Scientific Advisory Board	11.6yrs	데이터 없음	데이터 없음
Nancy Simonian	Director	11.6yrs	US$1.49m	0.66% € 49.5k
Gerard Evan	Member of Scientific Advisory Board	11.6yrs	데이터 없음	데이터 없음
Scott Biller	Member of Scientific Advisory Board	11.6yrs	데이터 없음	데이터 없음
Bradley Bernstein	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Stefan Knapp	Member of Scientific Advisory Board	11.6yrs	데이터 없음	데이터 없음
Aviv Regev	Member of Scientific Advisory Board	11.6yrs	데이터 없음	데이터 없음
Chris Vakoc	Member of Scientific Advisory Board	11.6yrs	데이터 없음	데이터 없음

11.6yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: 0S90 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.6 년).

Syros Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Chief Financial Officer recently bought €146k worth of stock

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Insufficient new directors

Insider recently bought €108k worth of stock

Insufficient new directors

Recent updates

New major risk - Revenue and earnings growth

Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Chief Financial Officer recently bought €146k worth of stock

New minor risk - Profitability

Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

First half 2024 earnings released: US$0.69 loss per share (vs US$2.15 loss in 1H 2023)

Syros Pharmaceuticals, Inc. to Report Q2, 2024 Results on Jul 31, 2024

New minor risk - Profitability

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023)

Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$5.81 loss per share (vs US$7.49 loss in FY 2022)

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Forecast to breakeven in 2026

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Third quarter 2023 earnings released: US$1.43 loss per share (vs US$3.21 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: US$1.30 loss per share (vs US$5.40 loss in 2Q 2022)

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings released: US$0.85 loss per share (vs US$3.99 loss in 1Q 2022)

Full year 2022 earnings released: US$7.49 loss per share (vs US$13.84 loss in FY 2021)

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Third quarter 2022 earnings released: US$3.21 loss per share (vs US$4.14 loss in 3Q 2021)

Insufficient new directors

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought €108k worth of stock

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.36 loss in 2Q 2021)

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.23 loss in 1Q 2021)

Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Syros Pharmaceuticals Provides Update on its Clinical Development Programs and Outlined its Strategic Priorities and Upcoming Expected Milestones

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.43 loss in 3Q 2020)

Syros Pharmaceuticals, Inc. Presents New Data from Phase 1 Trial of Sy-5609 and Details Three-Pronged Combination Strategy to Advance Sy-5609 in Solid Tumors and Blood Cancer

Syros Pharmaceuticals Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML

Second quarter 2021 earnings released: US$0.36 loss per share (vs US$0.38 loss in 2Q 2020)

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.39 loss in 1Q 2020)

New 90-day low: €6.60

Full year 2020 earnings released: US$1.83 loss per share (vs US$1.88 loss in FY 2019)

Revenue beats expectations

Syros Pharmaceuticals, Inc. announced that it has received $20 million in funding from Oxford Finance LLC

New 90-day high: €8.75

Syros Pharmaceuticals, Inc. Announces the New Clinical Data from its Phase 2 Trial Evaluating SY-1425

Revenue beats expectations

Third quarter 2020 earnings released: US$0.43 loss per share

Syros Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €6.50